INSTI® HCV (Hepatitis C Virus) Antibody Self-Test Contrived Result Interpretation
NCT ID: NCT06357819
Last Updated: 2024-04-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
405 participants
OBSERVATIONAL
2023-10-12
2023-12-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Trial of Hepatitis C Self-Testing in the Hands of Untrained Lay Users
NCT06369116
HCV Self-testing in Malaysia
NCT04982718
Same-visit Hepatitis C Testing and Treatment (The QuickStart Study)
NCT05016609
Evaluation Study of HCV RDTs in Fresh Samples
NCT04139941
Comparison of OraQuick HCV Rapid Antibody Test and Standard Serologic Screening for Hepatitis C: Validity, Acceptability and Impact on Linkage to Care
NCT02084719
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary Objectives were to document and record the following:
•Successful interpretation of contrived test results using mock test devices (strong positive, weak positive, negative and a range of invalid results).
Depending on the device being evaluated participants received a contrived INSTI® HCV Antibody Self Test membrane unit.
Participants were asked to interpret "mock" results \[read contrived device results using the reference chart in the Instructions for Use (IFU)\].
Participants were recruited from the Ezintsha Research Site which was a low-prevalence area and the Yeoville Harm Reduction Site which was a high-prevalence area in the city of Johannesburg in the Republic of South Africa. For the purposes of this assessment, the participant population was the general population. The participants did not have any experience in conducting any rapid diagnostic self-test using standard test kits, nor were they familiar with the prospective HCVST devices prior to entering into this mock result interpretation assessment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Mock Result Interpretation
Testing with non-functional devices (Mock-ups) that are modified to display contrived results to assess the ability of previously untrained users to correctly interpret one of the possible results as defined by each device manufacturer (e.g., Negative/Non-Reactive, Positive/Reactive, Invalid etc.)
INSTI HCV Self Test
Each participant was provided with contrived INSTI membrane units by the study observer, in random order, and was asked to interpret the results using the INSTI HCV ST Instructions for Use.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
INSTI HCV Self Test
Each participant was provided with contrived INSTI membrane units by the study observer, in random order, and was asked to interpret the results using the INSTI HCV ST Instructions for Use.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to complete the required testing on the allocated testing day\[s\]
* Able to speak/read English
* ≥18 years of age
* Provide a level of education (minimum grade 7)
* A practicing medical healthcare professional \[doctor, nurse or counsellor that performs testing with Rapid Tests\]
* Has used blood-based RDT for self-testing previously, either HIV or HCV
* Any condition which, in the opinion of the facilitator, would make the participant unsuitable or unsafe for enrolment or could interfere with the completion of the mock result interpretation assessment, consent form and questionnaire etc. or bias the outcome
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
bioLytical Laboratories
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
bioLytical Laboratories Inc.
Richmond, British Columbia, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HSTAR010
Identifier Type: OTHER
Identifier Source: secondary_id
EZIMOM012
Identifier Type: OTHER
Identifier Source: secondary_id
CLS-017A
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.